Targeted Radioligand Therapy and Immunotherapy for Cancer Treatment

Dear Colleagues,

We are delighted to announce a call for submissions for this Special Issue of the International Journal of Molecular Sciences. This Special Issue aims to explore the latest developments, challenges and innovations at the intersection of targeted radioligand therapy and immunotherapy as potent modalities for cancer treatment.

Targeted radioligand therapy and immunotherapy have emerged as transformative approaches within the oncological landscape, offering new avenues for personalized and effective cancer treatment. The combination of these modalities holds significant promise in enhancing treatment outcomes, overcoming resistance mechanisms and improving patient survival rates.

We welcome original research articles, reviews, clinical studies, case reports and perspectives addressing various aspects of targeted radioligand therapy and immunotherapy in cancer treatment, including but not limited to, the following:

1. Mechanisms of action and biological interactions between targeted radioligand therapy and immunotherapy;
2. Preclinical and clinical efficacy of combined targeted radioligand therapy and immunotherapy in different cancer types;
3. Radiobiology and immunobiology of the tumor microenvironment in the context of combined therapy;
4. Novel strategies for optimizing the combination of targeted radioligand therapy and immunotherapy;
5. Novel biomarkers and prediction of response to combined therapy;
6. Technological advancements and innovations in targeted radioligand therapy and immunotherapy delivery;
7. Immunotherapy-based approaches for overcoming resistance to targeted radioligand therapy;
8. Radiomics and immunogenomics in predicting treatment response and patient outcomes;
9. Challenges and future directions in the clinical integration of targeted radioligand therapy and immunotherapy.

Dr. Jinda Fan
Dr. Carolina de Aguiar Ferreira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• targeted radioligand therapy
• immunotherapy
• receptor targeting
• tumor-specific antigens
• immune checkpoint inhibitors
• radiosensitization
• tumor microenvironment
• combination therapy